Zacks Research Issues Negative Estimate for Perrigo Earnings

Perrigo Company plc (NYSE:PRGO) – Investment analysts at Zacks Research decreased their FY2025 earnings per share estimates for shares of Perrigo in a research report issued on Wednesday, November 26th. Zacks Research analyst Team now forecasts that the company will post earnings of $2.76 per share for the year, down from their prior estimate of $2.95. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Perrigo’s current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Perrigo’s Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.76 EPS, Q4 2026 earnings at $0.82 EPS, FY2026 earnings at $2.99 EPS, Q2 2027 earnings at $0.71 EPS, Q3 2027 earnings at $0.80 EPS and FY2027 earnings at $3.16 EPS.

PRGO has been the subject of several other research reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Perrigo in a report on Tuesday, November 25th. Wall Street Zen cut Perrigo from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Jefferies Financial Group decreased their price objective on Perrigo from $27.00 to $23.00 and set a “hold” rating on the stock in a report on Monday, October 27th. Canaccord Genuity Group lowered their target price on Perrigo from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a $20.00 price target (down previously from $32.00) on shares of Perrigo in a research report on Thursday, November 6th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $22.50.

Perrigo Stock Performance

PRGO opened at $13.35 on Monday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.24 and a current ratio of 2.32. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -23.02 and a beta of 0.42. The company has a fifty day moving average of $18.66 and a 200 day moving average of $23.10. Perrigo has a fifty-two week low of $12.17 and a fifty-two week high of $30.93.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.05. Perrigo had a negative net margin of 1.86% and a positive return on equity of 9.09%. The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter last year, the business posted $0.81 earnings per share. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 16th. Shareholders of record on Friday, November 28th will be paid a $0.29 dividend. The ex-dividend date is Friday, November 28th. This represents a $1.16 dividend on an annualized basis and a yield of 8.7%. Perrigo’s dividend payout ratio (DPR) is presently -305.26%.

Insider Buying and Selling at Perrigo

In related news, EVP Abigail Lennox acquired 1,255 shares of the stock in a transaction on Monday, September 8th. The stock was bought at an average cost of $22.41 per share, with a total value of $28,124.55. Following the transaction, the executive vice president directly owned 1,255 shares in the company, valued at approximately $28,124.55. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Geoffrey M. Parker bought 7,500 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was bought at an average price of $14.18 per share, for a total transaction of $106,350.00. Following the completion of the purchase, the director directly owned 17,375 shares in the company, valued at approximately $246,377.50. This represents a 75.95% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Perrigo

Institutional investors have recently made changes to their positions in the company. State of Michigan Retirement System increased its holdings in Perrigo by 1.2% in the 2nd quarter. State of Michigan Retirement System now owns 33,058 shares of the company’s stock valued at $883,000 after purchasing an additional 400 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in shares of Perrigo by 54.6% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,201 shares of the company’s stock worth $32,000 after buying an additional 424 shares during the period. Amundi grew its stake in shares of Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after buying an additional 556 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Perrigo by 1.4% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 42,290 shares of the company’s stock valued at $1,130,000 after buying an additional 564 shares during the period. Finally, Harbor Capital Advisors Inc. lifted its position in shares of Perrigo by 1.0% during the second quarter. Harbor Capital Advisors Inc. now owns 57,625 shares of the company’s stock worth $1,540,000 after purchasing an additional 570 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.